How Long Does Lurbinectedin Stay in Breast Milk?
No direct studies measure lurbinectedin (Zepzelca) levels in human breast milk. Its presence is inferred from pharmacokinetics: the drug has a half-life of 51–125 hours (mean 82 hours), suggesting it could persist in milk for weeks after a single dose.[1][2] Clearance depends on hepatic metabolism via CYP3A4, with full elimination taking 5–7 half-lives, or up to 4–6 weeks.[3]
Why Is Breastfeeding Not Recommended with Lurbinectedin?
The prescribing information advises against breastfeeding during treatment and for at least 21 days after the final dose, based on the drug's long half-life and potential for serious toxicity in infants, including myelosuppression and hepatotoxicity.[1] Animal data show no specific milk transfer studies, but high plasma protein binding (99%) limits free drug availability while prolonging exposure.[2]
What Happens If an Infant Is Exposed via Breast Milk?
Risks mirror adult side effects: anemia, neutropenia, fatigue, and nausea, which could harm a breastfeeding infant's bone marrow and liver. No pediatric safety data exist, so exposure is contraindicated.[1][4] Monitor for these if accidental exposure occurs, and consult poison control.
How Does Lurbinectedin Compare to Other Chemotherapies in Milk Transfer?
Unlike shorter-half-life agents like doxorubicin (half-life 20–48 hours, detectable in milk 1–4 days), lurbinectedin's extended clearance exceeds most chemotherapies.[5] Platinum drugs like cisplatin clear faster (1–2 days), but all are avoided during lactation per guidelines.[6]
When Can Breastfeeding Safely Resume After Treatment?
Wait at least 21 days post-dose per label, though some experts suggest 4–6 weeks to ensure negligible levels based on half-life.[1][7] Pump and discard milk during this period. Lactation consultants recommend confirming via plasma levels if needed.
[1]: Zepzelca Prescribing Information
[2]: Lurbinectedin Pharmacokinetics - EMA Summary
[3]: DrugBank: Lurbinectedin
[4]: Drugs and Lactation Database (LactMed): Lurbinectedin
[5]: LactMed: Doxorubicin
[6]: LactMed: Cisplatin
[7]: ASCO Guidelines on Fertility and Lactation in Cancer